Inovio Pharmaceuticals (NASDAQ:INO) Raised to “Buy” at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by stock analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a report released on Monday, Marketbeat reports. The brokerage presently has a $5.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on the stock. Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their price target for the stock from $1.80 to $3.00 in a research report on Thursday, August 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 12th. Finally, Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Inovio Pharmaceuticals Price Performance

Inovio Pharmaceuticals stock opened at $0.60 on Monday. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.72. The firm has a market capitalization of $62.29 million, a price-to-earnings ratio of -0.66 and a beta of 1.71. The firm has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $1.27.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Research analysts expect that Inovio Pharmaceuticals will post -0.72 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at about $33,000. Engineers Gate Manager LP acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth approximately $37,000. Squarepoint Ops LLC grew its stake in shares of Inovio Pharmaceuticals by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,554 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its stake in Inovio Pharmaceuticals by 312.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 53,510 shares during the last quarter. Finally, LexAurum Advisors LLC bought a new stake in Inovio Pharmaceuticals during the third quarter worth approximately $118,000. 26.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.